Corcept Therapeutics | CORT - Net Income

Stock Price
56.37
Daily Change
-1.93 -3.31%
Monthly
28.23%
Yearly
-24.92%
Q2 Forecast
55.24

Corcept Therapeutics reported $-31.76M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Alaunos Therapeutics USD -1.16M 108K Sep/2025
ANI Pharmaceuticals USD 29.49M 2.86M Mar/2026
Ardelyx USD -407K 562K Dec/2025
Assertio Holdings USD -2.92M 753K Sep/2024
Aurora Cannabis CAD 1.82M 53.29M Dec/2025
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Canopy Growth CAD -62.63M 60.99M Dec/2025
Corcept Therapeutics USD -31.76M 56.05M Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
J&J USD 5.24B 119M Mar/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novartis USD 3.16B 747M Mar/2026
Novartis USD 2.41B 1.52B Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 2.92M 1.28M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Supernus Pharmaceuticals USD -2.29M 1.81M Mar/2026
TG Therapeutics USD 19.78M 3.26M Mar/2026